--- title: "Bionano Genomics | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 6.687 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286311208.md" datetime: "2026-05-13T20:18:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286311208.md) - [en](https://longbridge.com/en/news/286311208.md) - [zh-HK](https://longbridge.com/zh-HK/news/286311208.md) --- # Bionano Genomics | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 6.687 M Revenue: As of FY2026 Q1, the actual value is USD 6.687 M, beating the estimate of USD 6.568 M. EPS: As of FY2026 Q1, the actual value is USD -0.76, beating the estimate of USD -0.88. EBIT: As of FY2026 Q1, the actual value is USD -8.048 M. Bionano Genomics, Inc. operates as a single operating and reportable segment. #### Revenue - **Total Revenue**: Increased by $0.2 million, or 4%, to $6.7 million for the three months ended March 31, 2026, compared to $6.5 million for the same period in 2025. - **Product Revenue**: Increased by $0.1 million, or 1%, to $6.1 million for the three months ended March 31, 2026, from $6.0 million in the prior year period. - **Instrument Revenue**: Increased by $0.3 million, or 40%, to $1.0 million for the three months ended March 31, 2026, from $0.7 million in the prior year period, driven by an increase in OGM and Ionic instruments sold. - **Consumables Revenue**: Increased by $0.7 million, or 20%, to $3.9 million for the three months ended March 31, 2026, from $3.2 million in the prior year period, due to an increase in both the number and average selling price of flowcells sold. - **Software Revenue**: Decreased by -$0.8 million, or -40%, to $1.2 million for the three months ended March 31, 2026, from $2.1 million in the prior year period, primarily due to a decrease in VIA software licenses sold. - **Service and Other Revenue**: Increased by $0.1 million, or 31%, to $0.6 million for the three months ended March 31, 2026, from $0.5 million in the prior year period, mainly due to increased clinical service offerings and extended warranty/maintenance sales. #### Geographic Revenue (as a percentage of total revenue) - **Americas**: Accounted for 37.3% of total revenue in Q1 2026, down from 47.3% in Q1 2025. - **EMEA**: Accounted for 53.1% of total revenue in Q1 2026, up from 47.5% in Q1 2025. - **Asia Pacific**: Accounted for 9.6% of total revenue in Q1 2026, up from 5.2% in Q1 2025. - **United States**: Represented approximately 30% of total revenue in Q1 2026, down from 38% in Q1 2025. - **France**: Represented approximately 11% of total revenue in Q1 2026. #### Cost of Revenue - **Total Cost of Revenue**: Decreased by -$0.1 million, or -2%, to $3.4 million for the three months ended March 31, 2026, compared to $3.5 million for the same period in 2025. - **Cost of Product Revenue**: Increased by $0.2 million, or 5%, to $3.2 million for the three months ended March 31, 2026, from $3.1 million in the prior year period, due to higher instrument and consumable sales. - **Cost of Service and Other Revenue**: Decreased by -$0.2 million, or -51%, to $0.2 million for the three months ended March 31, 2026, from $0.5 million in the prior year period, primarily due to a non-recurring increase in warranty expense in the prior year. #### Gross Profit and Gross Margin - **Total Gross Profit**: Increased by $0.3 million, or 11%, to $3.3 million for the three months ended March 31, 2026, from $2.9 million in the prior year period. - **Total Gross Margin**: Increased to 49% for the three months ended March 31, 2026, from 46% in the prior year period. - **Product Gross Profit**: Decreased by -$0.1 million, or -2%, to $2.9 million for the three months ended March 31, 2026, from $3.0 million in the prior year period, due to decreased software sales and increased lower-margin instrument sales, offset by consumable sales. - **Product Gross Margin**: Decreased to 47% for the three months ended March 31, 2026, from 49% in the prior year period. - **Service and Other Gross Profit**: Increased by $0.4 million to $0.4 million for the three months ended March 31, 2026, from a gross loss of -$0.01 million in the prior year period. - **Service and Other Gross Margin**: Increased to 61% for the three months ended March 31, 2026, from -3% in the prior year period. #### Operating Expenses - **Research and Development (R&D) Expenses**: Increased by $0.8 million, or 32%, to $3.1 million for the three months ended March 31, 2026, from $2.4 million in the prior year period, due to increases in salaries, professional and consulting fees, and internal inventory consumption. - **Selling, General and Administrative (SG&A) Expenses**: Decreased by -$1.0 million, or -11%, to $8.0 million for the three months ended March 31, 2026, from $9.0 million in the prior year period, primarily due to a net decrease in headcount-related expenses and a decrease in professional and consulting fees, partially offset by the absence of a gain on lease modification recorded in the prior period and increased IT, travel, rent, and facility costs. - **Total Operating Expenses**: Decreased by -$0.3 million, or -2%, to $11.1 million for the three months ended March 31, 2026, from $11.4 million in the prior year period. #### Loss from Operations - **Loss from Operations**: Decreased by -$0.6 million, or -7%, to -$7.9 million for the three months ended March 31, 2026, from -$8.5 million in the prior year period. #### Other Income (Expense) - **Interest Income**: Decreased by -$0.1 million, or -23%, to $0.2 million for the three months ended March 31, 2026, from $0.3 million in the prior year period, due to a reduction in investments offset by higher returns. - **Other Income (Expense)**: Was -$0.6 million for the three months ended March 31, 2026, compared to an income of $5.1 million in the prior year period, primarily due to changes in fair value remeasurements of convertible debentures (a -$0.5 million net loss in 2026 vs. a $5.1 million net gain in 2025). #### Net Loss - **Net Loss**: Increased by -$5.2 million, or 168%, to -$8.3 million for the three months ended March 31, 2026, from -$3.1 million in the prior year period. #### Cash Flow - **Net Cash Used in Operating Activities**: Increased to -$5.7 million for the three months ended March 31, 2026, from -$2.8 million in the prior year period, primarily due to increased inventory purchases and higher salaries, wages, and benefits. - **Net Cash Provided by Investing Activities**: Was $5.5 million for the three months ended March 31, 2026, compared to -$14.1 million used in the prior year period, mainly due to the maturity of $54.1 million in available-for-sale securities, partially offset by purchases of $48.7 million in available-for-sale securities. - **Net Cash Provided by Financing Activities**: Decreased to $0.7 million for the three months ended March 31, 2026, from $10.9 million in the prior year period, primarily due to no principal payments on convertible debentures in 2026 (compared to $1.5 million in 2025) and lower gross proceeds from at-the-market stock sales ($0.7 million in 2026 vs. $13.3 million in 2025). #### Unique Operational Metrics - **Installed Base of OGM Systems**: Grew to 399 as of March 31, 2026, a 5% increase from 379 as of March 31, 2025. - **Flowcells Sold**: Increased by 17% to 8,178 for the three months ended March 31, 2026, from 6,994 in the same period of 2025. - **Remaining Performance Obligations**: Estimated at $1.3 million as of March 31, 2026, with 82.3% expected to be recognized in the remainder of 2026, 13.2% in 2027, and 4.5% in 2028. #### Future Outlook and Strategy Bionano Genomics, Inc. anticipates continued significant expenses and operating losses as it maintains sales and marketing, product improvements, and explores collaborations, alongside managing public company costs. Management has expressed substantial doubt about its ability to continue as a going concern within 12 months, necessitating additional capital through equity or debt financings. Without sufficient near-term funding, the company may need to curtail operations, and a strategy committee is evaluating options to maximize stakeholder value. ### Related Stocks - [BNGO.US](https://longbridge.com/en/quote/BNGO.US.md) ## Related News & Research - [Bionano Genomics Q1 revenue up 4%, margin improves; to retire convertible debt](https://longbridge.com/en/news/286311999.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)